Hibiskus BioPharma

Hibiskus is an early-stage pharmaceutical company dedicated to developing novel small-molecule cancer therapies, including TIR-199.TIR-199 is a potent proteasome inhibitor derived from the Syrbactin family of natural products. It was developed by the company's founders, Profs. Pirrung and Bachmann, who are respectively from the University of California, Riverside (UCR) and Michigan State University (MSU). UCR holds several patents related to the production of TIR-199 and its use in treating cancer and immune diseases.Hibiskus is currently conducting preclinical research on TIR-199. To date, studies have shown that it holds particular promise for the treatment of metastatic renal cell carcinoma (mRCC).